Haematological malignancies are a diverse group of cancers that affect the blood, bone marrow and lymphatic systems. Laboratory diagnosis of haematological malignancies is dependent on combining several technologies, including morphology, immunophenotyping, cytogenetics and molecular genetics correlated As part of the 2016 update to the NICE IOG, these models were systematically evaluated and recommendations produced to form the basis for quality standards for future development of SIHMDS. We provide a summary of the systematic review and recommendations. Although the recommendations pertain to the UK NHS, they have relevance to the modern delivery of diagnostic services internationally.
Introduction
National Institute for Health and Care Excellence (NICE) service guidance is based on the best available evidence of clinical and cost effectiveness, and is produced to help commissioners, NHS Trusts, managers, healthcare professionals and patients make informed choices about appropriate healthcare to improve the effectiveness and efficiency of healthcare services.
Haematological malignancies include leukaemias, lymphomas and myeloma and originate mainly in the bone marrow and lymph nodes. They are a diverse group of diseases affecting people of all ages, but with highest incidence among the elderly.
Prognosis and responsiveness to treatment of these conditions also varies widely.
Haematological malignancies accounted for 8.4% of all malignant disease (excluding non-melanoma skin cancer) diagnosed in England in the years 2001 to 2010 1 Accurate diagnosis of haematological malignancies involves haematological and histopathological cytomorphology, immunophenotyping by flow cytometry and/or immunohistochemistry, cytogenetics and molecular genetics, including cutting edge technologies, such as next generation sequencing (NGS). Clinical information is also essential, both at the time of specimen analysis and when discussing diagnostic reports in a multidisciplinary team meeting. This approach is built into the World Health Organisation (WHO) classification for all haematological malignancies and updates of this classification [2] [3] [4] provide a diagnostic framework that emphasises the importance of integrating all these modern diagnostic tests.
Historical evidence, based principally on lymphoma, supports between 5% and 15% of haematological malignancies being misdiagnosed, sometimes with major clinical consequences [5] [6] [7] . Such errors can be difficult to detect after a patient has been treated and so it is very important that the initial diagnosis is correct and supported by strong evidence from several independent investigative modalities.
In the United Kingdom (UK) the 2003 NICE Improving Outcomes Guidance (IOG) for
Haematological Malignancies emphasised the importance of an integrated diagnostic approach to haematological malignancies 8 . The original guidance defined two levels of haematological malignancy diagnostic service -a local service, which provides initial assessment of specimens and a specialist laboratory service. A specialist service uses predefined diagnostic pathways to analyse specimens using a variety of diagnostic modalities, then validates and correlates the results to produce an integrated diagnostic report. This approach has been gradually adopted across the country and the specialist laboratories are now known as Specialist Integrated
Haematological Malignancy Diagnostic Services (SIHMDS). The aim of this best practice review is to summarise the evidence and recommendations for SIHMDS laboratories included in the revised IOG for Haematological Malignancies. Although the NICE guidance will be most relevant to SIHMDS in England, the general principles will be relevant to specialised laboratory practitioners and healthcare providers who work in the field of cancer internationally.
Methods: Evidence review during NICE Improving Outcomes Guidance development in relation to SIHMDS a) Service configuration
Most of the published research on cancer topics focuses on clinical evaluations of treatment; little direct research has been carried out on the organisation and delivery of services.
b) Epidemiology
This was key to the review in order to understand the routes through which patients with haematological malignancies might present initially or at relapse to healthcare services, to inform the shape of these services.
Accurate capture of information on haematological malignancies nationally, despite recent improvements, is still challenging. Haematological malignancies are diverse, ranging from highly aggressive types to incidentally identified indolent conditions.
Certain chronic leukaemias rarely produce symptoms, and the recorded incidence of these conditions depends on whether blood samples are examined and on the criteria used for deciding whether there is a malignancy. Even when it is clear that there is a malignancy, identifying the specific type requires sophisticated diagnostic techniques and the integration of information from clinical and laboratory sources.
These results are not always available to the Cancer Registries and so some registrations fail to capture the precise diagnosis. This is particularly true of nonHodgkin lymphoma (NHL), a large and varied group of conditions, for which the ICD-10 coding may be inadequately detailed to separate distinct entities or present other challenges for accurate classification in routine practice.
Data sources for the guideline included the National Cancer Registration Service Hodgkin lymphoma, non-Hodgkin lymphoma (NHL) and myeloma. There are no haematological cancers for which incidence rates declined over that period.
Registration rates for haematological cancers may have changed because of better ascertainment of new cases and developments in both diagnosis and classification; therefore the changes seen may not represent true changes in incidence (table 1) 5-7, 9-24 .
Figure 1: Search Results
The evidence was considered to be of low quality overall as all the identified studies were retrospective case series and none of them directly compared integrated diagnostic services with other forms of diagnostic service. There was a high risk of bias based on the potential lack of blinding and the possibility of selection bias. One study (Engel-Nitz et al, 2014) however compared diagnostic outcomes between specialist haematology laboratories and other commercial laboratories, reporting that patients in the specialist laboratory cohort were more likely to undergo more complex diagnostic testing with 26% of patients undergoing molecular diagnostics compared with 9.3% in community based hospital laboratories. Patients in the specialist laboratory cohort were 23% more likely to reach a final diagnosis within a 30 day testing period when compared with community based hospital laboratories. In the model, both approaches of SIHMDS had a lower cost per diagnosis and higher QALYs per patient compared to local reporting with subsequent referral of a proportion of cases to the SIHMDS. When comparing SIHMDS structure, a colocated approach was estimated to be £19 cheaper per diagnosis compared with a networked approach, although this was not robust during sensitivity analysis.
Change in staffing, capital and set-up costs were not considered as part of the economic modelling with this varying widely across England. It was acknowledged that there may be a significant initial resource impact on some centres around obtaining laboratory accommodation, implementation of integrated IT systems and the appointment of dedicated SIHMDS staff.
There was no evidence to directly compare outcomes from co-located and networked haematology diagnostic services and strong conclusions regarding the preferred configuration of SIHMDS could not be drawn solely from the results of the economic model. One study 11 reported significantly better clinical outcomes for a specialist haematology diagnostic laboratory, but it was unclear from the information provided, whether this study directly compared co-located and networked services.
Communication with the author of the study added extra information about the comparisons made and the Guideline Committee debated whether this warranted a recommendation for a co-located diagnostic service to optimise integration of the increasingly complex range of tests involved in the diagnosis of haematological malignancies required to fulfil WHO specifications. There was consensus in the Guideline Committee that a co-located service was the optimal approach and that, because it allowed more effective processes and procedures to be put in place, better communication between laboratory personnel and better quality control, it should be recommended, despite the lack of strong evidence.
The Guideline Committee agreed that there were a number of geographical and infrastructural barriers to establishing a co-located service and that the priority in any diagnostic service was delivering a high quality service that produced timely integrated reports. Although this was likely to be best met through a service with all the component parts located on a single site, this would not always be feasible and so a networked service might be a more appropriate option for certain parts of England. To clarify the key service requirements, the Guideline Committee developed a set of consensus-based recommendations outlining the key organisational, structural and managerial parameters, which should be fulfilled by any SIHMDS, whether co-located or networked. No specific evidence was identified about paediatric diagnosis but the Guideline Committee considered that diagnosis of paediatric patients would follow the same diagnostic pathways as that of adult patients and so the recommendations should cover all age groups.
Recommendations
The following is a list of the new, updated recommendations for 2016. For all recommendations, the quality of the evidence was considered to be low.
The Guideline Committee considered that recommendations are most likely to be achieved if the component parts of the SIHMDS are located at a single site.  report diagnoses sub-typed by the current WHO classification.
All SIHMDS should have a predefined diagnostic pathway that is followed for each specimen type or clinical problem. The pathway should ensure that:
 the most appropriate diagnostic platforms are selected for a particular clinical situation to avoid unnecessary duplication  tests for each specimen are used to provide maximum levels of internal crossvalidation, using the current WHO principle of multi-parameter disease definitions  there is a robust process for report validation, including double reporting.
All SIHMDS should have an IT system that allows: If an urgent treatment decision is needed and local diagnostic workup will not reduce the speed or quality of the SIHMDS assessment and integrated reporting, local diagnostic laboratories should process and report on blood film, bone marrow aspirate and cerebrospinal fluid cytology specimens.
SIHMDS should release individual laboratory reports before the integrated report is produced, if there is an urgent clinical need. Others developed different models; some using co-located facilities and others using networked but geographically distinct laboratory facilities to produce integrated reports. As there were pros and cons associated with both models, the Guideline Committee considered an economic analysis as well as clinically important aspects in formulating their recommendations.
A fully co-located service is a logical and convenient means of delivering SIHMDS. It permits consolidation of expert diagnostic staff and expensive technologies and is more likely to result in reduced turn-around times, improved diagnostic accuracy, reduced need for repeat sampling and greater cost efficiency. This should in turn lead to more effective treatment and less anxiety for patients. However, there are a number of potential barriers to setting up co-located SIHMDS services, in particular the need to restructure services. Some laboratories such as histopathology and molecular genetics have a broad remit across all cancer and non-cancer specialities, which prevents separation of their haematological services into a co-located SIHMDS. In rural regions, geographically isolated and disparate units with relatively small populations may find this restructuring a challenge with particular regard to recruitment, job satisfaction and ability to effectively communicate and attend MDT meetings: although modern telecommunications and developing digitalization could mitigate some aspects.
Balancing potential benefits against challenges around service reconfiguration, staff satisfaction, haematology training provision and recruitment, there was agreement that these recommendations were in the best interests of the service and the patients.
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